Skip to main content
Top
Published in: BMC Public Health 1/2014

Open Access 01-12-2014 | Research article

The cost of anal cancer in England: retrospective hospital data analysis and Markov model

Authors: Sam T Keeping, Michael J Tempest, Stephanie J Stephens, Stuart M Carroll, Karen P Nugent, Sarah T O'Dwyer

Published in: BMC Public Health | Issue 1/2014

Login to get access

Abstract

Background

Anal cancer requires a multidisciplinary approach to treatment with often complex interventions. Little is known regarding the associated costs and resource use.

Methods

Patient records were extracted from a national hospital database to estimate the number of patients treated for anal cancer in England. Identified resource use was linked to published UK cost estimates to quantify the reimbursement of treatment through the Payment by Results system. A mathematical model was developed simultaneously to validate findings and to calculate the average 10-year cost of treating a squamous cell anal carcinoma case from diagnosis. The model utilised data from the Association of Coloproctology of Great Britain and Ireland's anal cancer position statement.

Results

On average, 1,564 patients were admitted to hospital and 389 attended an outpatient facility per year. The average annual cost per inpatient and outpatient ranged from £4,562-£5,230 and £1,146-£1,335, respectively. Based on the model estimates, the inflated cost per case was between £16,470-£16,652. Results were most sensitive to the mode of admission for primary treatment and the costs of staging/diagnosis (inflated range: £14,309-£23,264).

Conclusions

Despite limitations in the available data, these results indicate that the cost of treating anal cancer is significant. Further observational work is required in order to verify these findings.
Appendix
Available only for authorised users
Literature
1.
go back to reference Scholefield JH, Nugent KP: Anal cancer: position statement of the association of coloproctology of Great Britain and Ireland introduction. Colorectal Dis. 2011, 13 (1): 1-2. 10.1111/j.1463-1318.2010.02508.x.CrossRefPubMed Scholefield JH, Nugent KP: Anal cancer: position statement of the association of coloproctology of Great Britain and Ireland introduction. Colorectal Dis. 2011, 13 (1): 1-2. 10.1111/j.1463-1318.2010.02508.x.CrossRefPubMed
3.
go back to reference Daling JR, Weiss NS, Hislop TG, Maden C, Coates RJ, Sherman KJ, Ashley RL, Beagrie M, Ryan JA, Corey L: Sexual practices, sexually transmitted diseases, and the incidence of anal cancer. N Engl J Med. 1987, 317: 973-977. 10.1056/NEJM198710153171601.CrossRefPubMed Daling JR, Weiss NS, Hislop TG, Maden C, Coates RJ, Sherman KJ, Ashley RL, Beagrie M, Ryan JA, Corey L: Sexual practices, sexually transmitted diseases, and the incidence of anal cancer. N Engl J Med. 1987, 317: 973-977. 10.1056/NEJM198710153171601.CrossRefPubMed
4.
go back to reference Czoski-Murray C, Karnon J, Jones R, Smith K, Kinghorn G: Cost-effectiveness of screening high-risk HIV-positive men who have sex with men (MSM) and HIV-positive women for anal cancer. Health Technol Assess. 2010, 14: 1-101. iii–iv, ix–xCrossRef Czoski-Murray C, Karnon J, Jones R, Smith K, Kinghorn G: Cost-effectiveness of screening high-risk HIV-positive men who have sex with men (MSM) and HIV-positive women for anal cancer. Health Technol Assess. 2010, 14: 1-101. iii–iv, ix–xCrossRef
6.
go back to reference Grulich AE, Poynten IM, Machalek DA, Jin F, Templeton DJ, Hillman RJ: The epidemiology of anal cancer. Sex Health. 2012, 9: 504-508. 10.1071/SH12070.CrossRefPubMed Grulich AE, Poynten IM, Machalek DA, Jin F, Templeton DJ, Hillman RJ: The epidemiology of anal cancer. Sex Health. 2012, 9: 504-508. 10.1071/SH12070.CrossRefPubMed
7.
go back to reference Crum-Cianflone NF, Hullsiek KH, Marconi VC, Ganesan A, Weintrob A, Barthel RV, Agan BK: Anal cancers among HIV-infected persons: HAART is not slowing rising incidence. AIDS. 2010, 24: 535-543. 10.1097/QAD.0b013e328331f6e2.CrossRefPubMedPubMedCentral Crum-Cianflone NF, Hullsiek KH, Marconi VC, Ganesan A, Weintrob A, Barthel RV, Agan BK: Anal cancers among HIV-infected persons: HAART is not slowing rising incidence. AIDS. 2010, 24: 535-543. 10.1097/QAD.0b013e328331f6e2.CrossRefPubMedPubMedCentral
8.
go back to reference Kronfli M, Glynne-Jones R: Chemoradiotherapy in anal cancer. Colorectal Dis. 2011, 13 (Suppl 1): 33-38.CrossRefPubMed Kronfli M, Glynne-Jones R: Chemoradiotherapy in anal cancer. Colorectal Dis. 2011, 13 (Suppl 1): 33-38.CrossRefPubMed
9.
go back to reference Glynne-Jones R, Northover JMA, Cervantes A: Anal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010, 21 (Suppl 5): v87-v92.CrossRefPubMed Glynne-Jones R, Northover JMA, Cervantes A: Anal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010, 21 (Suppl 5): v87-v92.CrossRefPubMed
10.
go back to reference Renehan AG, Saunders MP, Schofield PF, O’Dwyer ST: Patterns of local disease failure and outcome after salvage surgery in patients with anal cancer. Br J Surg. 2005, 92: 605-614. 10.1002/bjs.4908.CrossRefPubMed Renehan AG, Saunders MP, Schofield PF, O’Dwyer ST: Patterns of local disease failure and outcome after salvage surgery in patients with anal cancer. Br J Surg. 2005, 92: 605-614. 10.1002/bjs.4908.CrossRefPubMed
11.
go back to reference Renehan AG, O’Dwyer ST: Initial management through the anal cancer multidisciplinary team meeting. Colorectal Dis. 2011, 13 (Suppl 1): 21-28.CrossRefPubMed Renehan AG, O’Dwyer ST: Initial management through the anal cancer multidisciplinary team meeting. Colorectal Dis. 2011, 13 (Suppl 1): 21-28.CrossRefPubMed
12.
go back to reference National Institute for Health and Clinical Excellence (NICE): Guidance on Cancer Services. Improving Outcomes in Urological Cancer - The Manual. 2002, London, UK: National Institute for Clinical Excellence, 83-85. National Institute for Health and Clinical Excellence (NICE): Guidance on Cancer Services. Improving Outcomes in Urological Cancer - The Manual. 2002, London, UK: National Institute for Clinical Excellence, 83-85.
13.
go back to reference Jit M, Chapman R, Hughes O, Choi YH: Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model. BMJ. 2011, 343: d5775-10.1136/bmj.d5775.CrossRefPubMedPubMedCentral Jit M, Chapman R, Hughes O, Choi YH: Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model. BMJ. 2011, 343: d5775-10.1136/bmj.d5775.CrossRefPubMedPubMedCentral
14.
go back to reference Tappenden P, Chilcott J, Eggington S, Patnick J, Sakai H, Karnon J: Option appraisal of population-based colorectal cancer screening programmes in England. Gut. 2007, 56: 677-684. 10.1136/gut.2006.095109.CrossRefPubMed Tappenden P, Chilcott J, Eggington S, Patnick J, Sakai H, Karnon J: Option appraisal of population-based colorectal cancer screening programmes in England. Gut. 2007, 56: 677-684. 10.1136/gut.2006.095109.CrossRefPubMed
15.
go back to reference Wolstenholme JL, Whynes DK: Stage-specific treatment costs for cervical cancer in the United Kingdom. Eur J Cancer. 1998, 34: 1889-1893. 10.1016/S0959-8049(98)00232-9.CrossRefPubMed Wolstenholme JL, Whynes DK: Stage-specific treatment costs for cervical cancer in the United Kingdom. Eur J Cancer. 1998, 34: 1889-1893. 10.1016/S0959-8049(98)00232-9.CrossRefPubMed
16.
go back to reference De Rijke JM, van der Putten HWHM, Lutgens LCHW, Voogd AC, Kruitwagen RFPM, van Dijck JAAM, Schouten LJ: Age-specific differences in treatment and survival of patients with cervical cancer in the southeast of The Netherlands, 1986-1996. Eur J Cancer. 2002, 38: 2041-2047. 10.1016/S0959-8049(02)00315-5.CrossRefPubMed De Rijke JM, van der Putten HWHM, Lutgens LCHW, Voogd AC, Kruitwagen RFPM, van Dijck JAAM, Schouten LJ: Age-specific differences in treatment and survival of patients with cervical cancer in the southeast of The Netherlands, 1986-1996. Eur J Cancer. 2002, 38: 2041-2047. 10.1016/S0959-8049(02)00315-5.CrossRefPubMed
17.
go back to reference Scholefield JH, Harris D, Radcliffe A: Guidelines for management of anal intraepithelial neoplasia. Colorectal Dis. 2011, 13 (Suppl 1): 3-10.CrossRefPubMed Scholefield JH, Harris D, Radcliffe A: Guidelines for management of anal intraepithelial neoplasia. Colorectal Dis. 2011, 13 (Suppl 1): 3-10.CrossRefPubMed
18.
go back to reference Salmo E, Haboubi N: Anal cancer: pathology, staging and evidence-based minimum data set. Colorectal Dis. 2011, 13 (Suppl 1): 11-20.CrossRefPubMed Salmo E, Haboubi N: Anal cancer: pathology, staging and evidence-based minimum data set. Colorectal Dis. 2011, 13 (Suppl 1): 11-20.CrossRefPubMed
19.
21.
go back to reference Renehan AG, O’Dwyer ST: Management of local disease relapse. Colorectal Dis. 2011, 13 (Suppl 1): 44-52.CrossRefPubMed Renehan AG, O’Dwyer ST: Management of local disease relapse. Colorectal Dis. 2011, 13 (Suppl 1): 44-52.CrossRefPubMed
22.
go back to reference Information Centre: The HES Protocol (June 2009): instructions for handling the data. 2009, London: Information Centre Information Centre: The HES Protocol (June 2009): instructions for handling the data. 2009, London: Information Centre
29.
go back to reference Northover J, Glynne-Jones R, Sebag-Montefiore D, James R, Meadows H, Wan S, Jitlal M, Ledermann J: Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). Br J Cancer. 2010, 102: 1123-1128. 10.1038/sj.bjc.6605605.CrossRefPubMedPubMedCentral Northover J, Glynne-Jones R, Sebag-Montefiore D, James R, Meadows H, Wan S, Jitlal M, Ledermann J: Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). Br J Cancer. 2010, 102: 1123-1128. 10.1038/sj.bjc.6605605.CrossRefPubMedPubMedCentral
30.
go back to reference Daling JR, Madeleine MM, Schwartz SM, Shera KA, Carter JJ, McKnight B, Porter PL, Galloway DA, McDougall JK, Tamimi H: A population-based study of squamous cell vaginal cancer: HPV and cofactors. Gynecol Oncol. 2002, 84: 263-270. 10.1006/gyno.2001.6502.CrossRefPubMed Daling JR, Madeleine MM, Schwartz SM, Shera KA, Carter JJ, McKnight B, Porter PL, Galloway DA, McDougall JK, Tamimi H: A population-based study of squamous cell vaginal cancer: HPV and cofactors. Gynecol Oncol. 2002, 84: 263-270. 10.1006/gyno.2001.6502.CrossRefPubMed
31.
go back to reference De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S: Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer. 2009, 124: 1626-1636. 10.1002/ijc.24116.CrossRefPubMed De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S: Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer. 2009, 124: 1626-1636. 10.1002/ijc.24116.CrossRefPubMed
32.
go back to reference Hoots BE, Palefsky JM, Pimenta JM, Smith JS: Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions. Int J Cancer. 2009, 124: 2375-2383. 10.1002/ijc.24215.CrossRefPubMed Hoots BE, Palefsky JM, Pimenta JM, Smith JS: Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions. Int J Cancer. 2009, 124: 2375-2383. 10.1002/ijc.24215.CrossRefPubMed
33.
go back to reference Ogunbiyi OA, Scholefield JH, Robertson G, Smith JH, Sharp F, Rogers K: Anal human papillomavirus infection and squamous neoplasia in patients with invasive vulvar cancer. Obstet Gynecol. 1994, 83: 212-216.PubMed Ogunbiyi OA, Scholefield JH, Robertson G, Smith JH, Sharp F, Rogers K: Anal human papillomavirus infection and squamous neoplasia in patients with invasive vulvar cancer. Obstet Gynecol. 1994, 83: 212-216.PubMed
34.
go back to reference Parkin DM, Bray F: Chapter 2: the burden of HPV-related cancers. Vaccine. 2006, 24 (Suppl 3): S3/11-25. Parkin DM, Bray F: Chapter 2: the burden of HPV-related cancers. Vaccine. 2006, 24 (Suppl 3): S3/11-25.
35.
go back to reference Ogunbiyi OA, Scholefield JH, Smith JH, Polacarz SV, Rogers K, Sharp F: Immunohistochemical analysis of p53 expression in anal squamous neoplasia. J Clin Pathol. 1993, 46: 507-512. 10.1136/jcp.46.6.507.CrossRefPubMedPubMedCentral Ogunbiyi OA, Scholefield JH, Smith JH, Polacarz SV, Rogers K, Sharp F: Immunohistochemical analysis of p53 expression in anal squamous neoplasia. J Clin Pathol. 1993, 46: 507-512. 10.1136/jcp.46.6.507.CrossRefPubMedPubMedCentral
Metadata
Title
The cost of anal cancer in England: retrospective hospital data analysis and Markov model
Authors
Sam T Keeping
Michael J Tempest
Stephanie J Stephens
Stuart M Carroll
Karen P Nugent
Sarah T O'Dwyer
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2014
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/1471-2458-14-1123

Other articles of this Issue 1/2014

BMC Public Health 1/2014 Go to the issue